HDL-cholesterol: An important factor to evaluate a cardlovascular risk in practice;HDL-cholestérol: Place de son dosage dans l'évaluation d'un risque cardiovasculaire

Annales de Biologie Clinique

Volumn 61, Issue 5, 2003, Pages 549-556

  Guinchard Foulon, E ^a   Rodriguez Lafrasse, C ^a   Rousson, R ^a  

^a Hop Cardiovasculaire/P   (France)

Author keywords

Assay; Cholesterol reverse transport; HDL cholesterol

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYPOCHOLESTEROLEMIC AGENT;

BLOOD; BLOOD ANALYSIS; CARDIOVASCULAR DISEASE; HUMAN; METHODOLOGY; OBESITY; PATHOPHYSIOLOGY; REVIEW; RISK FACTOR;

ANTICHOLESTEREMIC AGENTS; BLOOD CHEMICAL ANALYSIS; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; HUMANS; OBESITY; RISK FACTORS;

EID: 0141674765     PISSN: 00033898     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (25)

1. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med 1977; 62: 707-14.
2. Kannel WB, Wilson PW. Efficacy of lipid profiles in prediction of coronary disease. Am Heart J 1992; 124: 768-74.
3. Miller GJ, Miller NE. Plasma-high-density-lipoprotein concentration and development of ischaemic heart-disease. Lancet 1975; 1: 6-9.
4. Schaefer EJ. New recommendations for the diagnosis and treatment of plasma lipid abnormalities. Nutr Rev 1993; 51: 246-53.
5. Egloff M, Leglise D, Duvillard L, et al. Évaluation multicentrique sur différents automates d'analyses de trois méthodes de dosage direct du cholestérol-HDL. Ann Biol Clin 1999; 57: 561-72.
6. Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans affairs high-density lipoprotein cholesterol intervention trial study group. N Engl J Med 1999; 341: 410-8.
7. Chong PH, Bachenheimer BS. New and future treatments in dyslipidaemia and atherosclerosis. Drugs 2000; 60: 55-93.
8. Goldbourt U, Yaari S, Medalie JH. Isolated low HDL cholesterol as a risk factor for coronary heart disease mortality. A 21-year follow-up of 8000 men. Arterioscler Thromb Vasc Biol 1997; 17: 107-13
9. Real JT, Chaves FJ, Martinez-Uso I, Garcia-Garcia AB, Ascaso JF, Carmena R. Importance of HDL cholesterol levels and the total/ HDL cholesterol ratio as a risk factor for coronary heart disease in molecularly defined heterozygous familial hypercholesterolaemia. Eur Heart J 2001; 22: 465-71.
10. Hausmann D, Johnson JA, Sudhir K, et al. Angiographically silent atherosclerosis detected by intravascular ultrasound in patients with familial hypercholesterolemia and familial combined hyperlipidemia: correlation with high density lipoproteins. J Am Coll Cardiol 1996; 27: 1562-70.
11. Kwiterovich PO Jr. The metabolic pathways of high-density lipoprotein, low-density lipoprotein, and triglycerides: a current review. Am J Cardiol 2000; 86: 5L-10L.
12. Fielding CJ, Fielding PE. Molecular physiology of reverse cholesterol transport. J Lipid Res 1995; 36: 211-28.
13. Harris N, Galpchian V, Rifai N. Three routine methods for measuring high-density lipoprotein cholesterol compared with the reference method. Clin Chem 1996; 42: 738-43.
14. Huang YC, Kao JT, Tsai KS. Evaluation of two homogeneous methods for measuring high-density lipoprotein cholesterol. Clin Chem 1997; 43: 1048-55.
15. Nauck M, Marz W, Haas B, Wieland H. Homogeneous assay for direct determination of high-density lipoprotein cholesterol evaluated. Clin Chem 1996; 42: 424-9.
16. Sugiuchi H, Uji Y, Okabe H, et al. Direct measurement of high-density lipoprotein cholesterol in serum with polyethylene glycol-modified enzymes and sulfated alpha-cyclodextrin. Clin Chem 1995; 41: 717-23.
17. Warnick GR, Wood PD. National cholesterol education program recommendations for measurement of high-density lipoprotein cholesterol: executive summary. The national cholesterol education program working group on lipoprotein measurement. Clin Chem 1995; 41: 1427-33.
18. Caudill SP, Cooper GR, Smith SJ, Myers GL. Assessment of current national cholesterol education program guidelines for total cholesterol triglyceride, HDL-cholesterol, and LDL-cholesterol measurements. Clin Chem 1998; 44: 1650-8.
19. Oliver WR Jr, Shenk JL, Snaith MR, et al. A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport. Proc Natl Acad Sci USA 2001; 98: 5306-11.
20. Despres JP. Increasing high-density lipoprotein cholesterol: an update on fenofibrate. Am J Cardiol 2001; 88: 30N-36N.
21. Atmeh RF, Shepherd J, Packard CJ. Subpopulations of apolipoprotein A-I in human high-density lipoproteins. Their metabolic properties and response to drug therapy. Biochim Biophys Acta 1983; 751: 175-88.
22. Chong PH, Bachenheimer BS. New and future treatments in dyslipidaemia and atherosclerosis. Drugs 2000; 60: 55-93.
23. Oliver WR Jr, Shenk JL, Snaith MR, et al. A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport. Proc Natl Acad Sci USA 2001; 98: 5306-11.
24. Fruchart JC. Peroxisome proliferator-activated receptor-alpha activation and high-density lipoprotein metabolism. Am J Cardiol 2001; 88: 24N-29N.
25. Sakai T, Kamanna VS, Kashyap ML. Niacin, but not gemfibrozil, selectively increases LP-AI, a cardioprotective subfraction of HDL, in patients with low HDL cholesterol. Arterioscler Thromb Vasc Biol 2001; 21: 1783-9.